This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAREV Life Sciences Global（AREV）株式概要Operates as an early-stage life science discovery company in Canada. 詳細AREV ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去 1 年間で収益は10.2%増加しましたリスク分析意味のある時価総額がありません ( CA$3M )収益が 100 万ドル未満 ( CA$184K )マイナスの株主資本 株式の流動性は非常に低い +2 さらなるリスクすべてのリスクチェックを見るAREV Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW482,938 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA482,938 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.09542.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m186k2016201920222025202620282031Revenue CA$183.9kEarnings CA$27.3kAdvancedSet Fair ValueView all narrativesAREV Life Sciences Global Corp. 競合他社Craftport CannabisSymbol: CNSX:CFTMarket cap: CA$2.7mTHC Biomed IntlSymbol: CNSX:THCMarket cap: CA$3.3mAdastra HoldingsSymbol: CNSX:XTRXMarket cap: CA$1.1m1933 IndustriesSymbol: CNSX:TGIFMarket cap: CA$5.2m価格と性能株価の高値、安値、推移の概要AREV Life Sciences Global過去の株価現在の株価CA$0.0952週高値CA$0.2752週安値CA$0.065ベータ2.621ヶ月の変化0%3ヶ月変化0%1年変化-35.71%3年間の変化28.57%5年間の変化-95.71%IPOからの変化-94.23%最新ニュースお知らせ • Feb 06AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024.Board Change • Jun 16No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 20No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Mar 08No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 10AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from BoardAREV Life Sciences Global Corp. announced the resignation of Melvin Maxwell from the Board.Board Change • Jan 06No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.最新情報をもっと見るRecent updatesお知らせ • Feb 06AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024.Board Change • Jun 16No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 20No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Mar 08No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 10AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from BoardAREV Life Sciences Global Corp. announced the resignation of Melvin Maxwell from the Board.Board Change • Jan 06No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 24Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)Third quarter 2022 results: CA$0.008 loss per share. Revenue: CA$23.1k (down 13% from 3Q 2021). Net loss: CA$240.7k (loss widened 9.4% from 3Q 2021).Recent Insider Transactions • Nov 20Chairman & CEO recently bought CA$59k worth of stockOn the 11th of November, Michael Withrow bought around 578k shares on-market at roughly CA$0.10 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of CA$59k worth in shares.Board Change • Nov 16No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 29AREV Life Sciences Global Corp. Announces Management ChangesAREV Life Sciences Global Corp. announced the appointment of Dr. Andrew Levinson to the company’s Scientific Advisory Board. Dr. Levinson is dedicated to progressive direction in integrative health, Dr. Levinson is a functional medicine doctor and psychiatrist combining mainstream and alternative approaches together with comprehensive treatments. He has developed and commercialized a line of complementary products branded as “Vitality Health and Wellness" which he sells though his clinics and concierge service. Dr. Levinson received both his Bachelor of Science in Psychobiology and his Medical Doctorate from University of Miami. While at University of Miami, in 1993 Dr. Levinson created and chaired an alternative medicine conference which was integrated into the medical school#s curriculum for both students and professors. He also pursued academia as an Assistant Professor in the Department of Psychiatry at Florida International University’s College of Medicine. Dr. Levinson has affiliation with: the International AIDS Society (IAS), the International Association of Providers of AIDS Care (IAPAC), the American Academy of HIV Medicine (AAHIVM), and the Infectious Disease Society of America (IDSA). The company also announced the resignation of Mr. Kevin Phelps as Chief Operating Officer ("COO") of the Company. Mr. Phelps feels that the Company is at a critical step in its development, and onsite leadership is needed at this time. Due to Mr. Phelps being located in New York, and given the challenges of International travel given the pandemic, he was no longer the best fit for this role. Mr. Phelps will continue on as a member of the Board of Directors of the Company.Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)Second quarter 2022 results: CA$0.026 loss per share. Revenue: CA$10.2k (down 76% from 2Q 2021). Net loss: CA$772.9k (loss widened 11% from 2Q 2021).お知らせ • Aug 18AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory BoardAREV Life Sciences Global Corp. announced the appointment of Sateesh Apte MD to the Scientific Advisory Board (the SAB) of AREV. AREV Life Sciences announced the appointment of Sateesh Apte MD to its Scientific Advisory Board, as part of the current scale up for launching clinical studies of SUSTAINNTM for treating Serious Acute Malnutrition in Low & Middle Income Countries. "LMIC". Dr Apte"s expertise in neurological pathogenesis will complement AREV's focus on positioning SUSTAINNTM to address the cognitive preservation of children experiencing serious acute malnutrition, which causes brain damage in millions of malnourished children a year. Said Mike Withrow, CEO of AREV Life Sciences Dr. Apte's appointment to the SAB of AREV is a critical step in successfully designing studies to demonstrate the clinical value of SUSTAINN in treating SAM. Dr. Apte specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences. Dr. Apte"s graduate training was at Haffkine Institute in Mumbai, India, The Pasteur Institute in Paris, France, at Harvard Medical School in Boston and at Stanford University in California. His professional appointments have included active staff positions at the VA Medical Center and Valley Memorial Hospital in Livermore, CA; ValleyCare Medical Center in Pleasanton, CA, and directorships with PainCare Medical Clinic, and the Sleep Disorders Center in San Ramon and Pleasanton, CA. He most recently served as President and CEO of Northern California Physicians Associates Inc. and Alpha Medical Group Inc. (1986-1992) He served as President and CEO of ImmunoScience Inc. in Pleasanton, CA until 2019. Dr. Apte has authored and co-authored a number of articles for medical journals and has several publications pending.Reported Earnings • May 03Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)Full year 2021 results: CA$0.051 loss per share (up from CA$0.068 loss in FY 2020). Revenue: CA$255.0k (up 34% from FY 2020). Net loss: CA$990.3k (loss narrowed 5.6% from FY 2020). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 20AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of DirectorsAREV Life Sciences Global Corporation announced the appointment of Brian V. Elliott, B Comm to its Board of Directors. Brian V. Elliott is an international strategist and leader exhibiting over 35 years in Senior Management positions in the pharmaceutical industry and the health related public sectors. He has provided10 years of service with the Irish Government Industrial Development Authority in Ireland, France, and Lesotho.お知らせ • Apr 09AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating OfficerAREV Life Sciences Global Corp. announced the appointment of Kevin Phelps, CPA as Chief Operating Officer. In its current phase of growth and development, AREV Life Sciences Global Corporation appoints Kevin Phelps, CPA and AREV Board Member to the role of Chief Operating Officer. Kevin Phelps brings 40 years of experience in biotech and general business sectors to AREV. He has served in roles as CEO, CFO and VP Business Development throughout several executive teams.お知らせ • Feb 18AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory CommitteeAREV Life Sciences Global Corp. announced the appointment of Douglas Sorocco to its Scientific Advisory Committee and IP Council and the company's extension of services with Strategic Health Resources LLC.お知らせ • Dec 12AREV Life Sciences Settles Pending Litigation with HarveyAREV Life Sciences Global Corp. announced that it has reached a confidential settlement with Matthew Harvey, the vendor of the BC Bud Depot Assets, during a formal mediation prior to Trial. The Company announced on January 31, 2020 that the Company had commenced litigation in the Supreme Court of British Columbia over the breaches of Agreement by the Defendant, Matthew Harvey, the vendor of the BC Bud Depot Assets. The Company is very pleased with the outcome of the mediation, but cannot disclose the details of the settlement as the Mediation process is confidential.Reported Earnings • Dec 02Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.009 loss per share (vs CA$0.009 loss in 3Q 2020). Revenue: CA$26.5k (down 46% from 3Q 2020). Net loss: CA$219.9k (loss widened 39% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.お知らせ • Dec 01AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million on November 30, 2021. AREV Life Sciences Global Corp. (CNSX:AREV) completed the acquisition of Wright and Well Essentials Inc. on November 30, 2021.Recent Insider Transactions Derivative • Nov 21Chairman & CEO exercised options to buy CA$200k worth of stock.On the 19th of November, Michael Withrow exercised options to buy 1m shares at a strike price of around CA$0.08, costing a total of CA$80k. This transaction amounted to 11% of their direct individual holding at the time of the trade. Since December 2020, Michael's direct individual holding has increased from 8.29m shares to 9.47m. Company insiders have collectively sold CA$83k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Nov 21Chairman & CEO recently sold CA$125k worth of stockOn the 17th of November, Michael Withrow sold around 499k shares on-market at roughly CA$0.25 per share. This was the largest sale by an insider in the last 3 months. Michael has been a seller over the last 12 months, reducing personal holdings by CA$382k.Reported Earnings • Aug 28Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: CA$43.2k (down 20% from 2Q 2020). Net loss: CA$695.3k (loss widened 153% from 2Q 2020).Reported Earnings • Jun 06First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$42.6k (up 25% from 1Q 2020). Net loss: CA$566.5k (loss widened 400% from 1Q 2020).お知らせ • Jun 02AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based DrugsAREV NANOTEC BRANDS INC. announced that it has expanded its extraction results to Clinical Characterization of Compounds and provides this update of corporate developments consistent with its news announcements. In the first five months of 2021, AREV has advanced its core competencies in extraction systems, functional ingredient production, and natural product formulations, expanding its know-how into innovative plant compound identification and medicinal characterization for utility in the company’s development of advanced-stage nutritional foods and discovery of plant-based drugs (or phytomedicinalization). AREV is engaging scientists to characterize compounds for its proprietary ingredients while building AREV’s team of preclinical drug discovery partners in the company’s rational drug design, driven by molecular epidemiology.お知らせ • Apr 01AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in fundingOn March 31, 2021, AREV NanoTec Brands Inc. (CNSX:AREV) closed the transaction. The company announced that it has issued 2,680,000 units for gross proceeds of CAD 670,000. The transaction involved participation from strategic investors, including an insider for 400,000 units. the transaction was undersubscribed.お知らせ • Mar 03Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate DevelopmentAREV NanoTec Brands Inc. announced that the Company has appointed Chad S. Johnson, Esq., as Special Counsel for Corporate Development. Complementing AREVs announced corporate and development activities, Mr. Johnson and his staff will serve AREV in a variety of capacities, including media strategy development, government affairs and legislative advocacy, facilitation of scientific advisory appointments, coordination of trade organization memberships, organization of global scientific conference operations, and management of relationships with clinical societies and academies. Mr. Johnson will also assist in developing collaborations with academic research institutions and private sector partners to accelerate AREVs pre-clinical drug discovery platform.お知らせ • Feb 25AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of DirectorsAREV NanoTec Brands Inc. announced the addition of Kevin J. Phelps to its Board of Directors. Mr. Phelps has a long history in the biotechnology and drug discovery industries, currently serving as the CEO of Immune Therapeutics Inc., and as Chairman of OyaGen Inc. Mr. Phelps began his career as a CPA with Price Waterhouse Coopers and the executive management team of Eastman Kodak Company and its affiliate, Genencor International Inc., which Mr. Phelps served as CFO and EVP of Business Development. He has also served as CFO of Vaccinex Inc. Mr. Phelps went on to join Trillium Group, LLC.お知らせ • Feb 20AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory BoardAREV NanoTec Brands Inc. announced the appointment of Dr. Jay Noller to its Scientific Advisory Board. Dr. Jay Noller, PhD, is a globally recognized polymath in agriculture, environmental and earth sciences, archaeology, and visual arts. He has led organizations that provided diverse activities in education, research, extension, and public service relevant to seed production, soils and ecosystem services, small farms and community food systems, integrated pest management, and various approaches to natural resource management. He has served in numerous roles as leader or administrator of several enterprises that provide wheat, potatoes and other food commodities to the world at large as well as to food systems at community level.お知らせ • Feb 18AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral PathogensAREV NANOTEC BRANDS INC. announced that AREV is utilizing its proprietary extraction technologies and facilitating initial efforts to identify broad spectrum antiviral agents derived from medicinal photochemistry sources including bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia, identified in peer-reviewed publications as presenting a wide range of antiviral activity, and may demonstrate high affinity with viral protease inhibition. AREV’s current efforts to secure the antiviral characteristics of COVID-19’s Mpro which remains as the important drug target against COVID-19 infection, will involve grant solicitation from funding sources for pre-clinical discover include NSF’s Rapid Response Research (RAPID) program to mobilize funding for high priority projects and the NIH Consortium for Advancing Research on Botanical and Other Natural Products (CARBON) Program, working with the National Center for Complementary and Integrative Health (NCCIH) as well as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership and Biomedical Advanced Research and Development Authority (BARDA) to address the COVID-19 pandemic that are directing requests for proposals to numerous biopharmaceutical companies. More than 2,100 plant species globally have the potential for being used as medical plants and it has been estimated, that plant derived drugs constitute as much as 25% of the total therapeutics while in fast developing countries such as India and China, the contribution is as much as 80%.Is New 90 Day High Low • Feb 11New 90-day high: CA$0.42The company is up 367% from its price of CA$0.09 on 11 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 109% over the same period.お知らせ • Feb 10AREV Appoints Dr. Roscoe Moore to Join the Advisory BoardAREV NANOTEC BRANDS INC. announced the appointment of Dr. Roscoe Moore DVM, MPH, PhD, Former Assistant United States Surgeon General to the Scientific Advisory Board for AREV Nanotec Brands Inc, to provide strategic planning for AREV drug discovery planning, as a Senior Scientific Advisor.お知らせ • Feb 05AREV NanoTec Brands Inc. Corporate Update on Latest InnovationArev Nanotec Brands Inc. Corporate update on its continued work with natural materials, specifically Moringa. The company has been working with several plant, fungi and marine biomass including functional mushrooms, hops, frank-incense, myrrh, Kampot pepper, sea cucumber, ginseng and Moringa. Much of this work has been focused on the best way to extract actives and researching target compounds present in each of the natural phyto-matierials. As a result, the company has chosen Moringa to be the candidate for molecular screening for its antiviral properties. The company has secured organic supply from Priceless Farms in Uganda, which is working with AREV's Cambodian subsid-iary to establish Moringa as a permaculture crop on its 12 hectare parcel of land near Phnom Penh. The company will continue to update shareholders as progress is made on what is anticipated to be a fast moving initiative.お知らせ • Feb 03AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory BoardAREV NanoTec Brands Inc. appointed Dr. Uma V. A. Dhanabalan as Advisory Board. She is a Fellow of the American Academy of Family Physicians, a Diplomat Certified in Cannabinoid Medicine and a Medical Review Officer.お知らせ • Jan 26AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in fundingAREV NanoTec Brands Inc. (CNSX:AREV) announced a non-brokered private placement of up to of up to 2,900,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 725,000 on January 25, 2021. Each Unit will consist of one common Share and one common share purchase warrant, each whole warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.28 per share, on the date that is 24 months from the date of issuance of the warrants; except that, if over a period of 10 consecutive trading days between the date that is 4 months and a day from the date of issuance of the warrants and the date that the warrants would otherwise expire, the closing price of the company’s common shares on the Canadian Securities Exchange is at or exceeds CAD 0.75, then the company may, at its option, provide written notice to the warrant holders to exercise their warrants within 30 days of the date of the notice, failing which the warrants will expire. Securities issued by the company pursuant to the transaction will be subject to a four month and one day hold period in Canada commencing on the closing date. The company may pay finders’ fees in cash, shares or warrants, or a combination of the forgoing, subject to the Board approval and in accordance with the policies of the Canadian Securities Exchange.お知らせ • Jan 08AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLCAREV Brands International Ltd. (CNSX:AREV) announced a non brokered private placement of up to 1,000,000 units at a price of CAD 0.10 per unit for gross proceeds of up to CAD 100,000 on January 6, 2020. Each unit consists of one share and one common share purchase warrant. Each warrant is exercisable at a price of CAD 0.15 per share for 12 months from the date of issuance. The transaction included participation from returning strategic investor, Chiron Partners LLC.分析記事 • Jan 02How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...Is New 90 Day High Low • Dec 31New 90-day high: CA$0.22The company is up 175% from its price of CA$0.08 on 24 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 57% over the same period.Recent Insider Transactions • Dec 31Chairman & CEO recently sold CA$261k worth of stockOn the 24th of December, Michael Withrow sold around 2m shares on-market at roughly CA$0.15 per share. This was the largest sale by an insider in the last 3 months. Michael has been a seller over the last 12 months, reducing personal holdings by CA$87k.お知らせ • Dec 26AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune BoostAREV NANOTEC BRANDS INC. announced that it has received its' first trial run of its NaturVac Immune Boost. NaturVac is the company's proprietary blended Sea Cucumber, Turmeric and Astaxanthin known to Decrease oxidative stress on the heart and blood vessels, Vitamin D3 known to help to maintain immune function, Zinc known to help to maintain immune function and B12 known to help to form red blood cells. Sea cucumbers are rich in protein, Chondroitin sulphate niacin, and riboflavin and contain substances thought to influence human health, including: Coelomic fluid a compound that functions similarly to white blood cells in humans, Palmitic, stearic, and linoleic acid a fatty acids with potent antioxidant effects, Squalene a compound that acts the precursor to steroids and Triterpenoids a class of compounds thought to slow cancer growth. Naturvac has been formulated to provide pre-emptive approach to maintaining a healthy immune system. The trial run will be marketed under the company's BARE – People Brand.お知らせ • Dec 17AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP MarketingAREV Brands International Ltd. announced the appointment of Mr. Don Shaxon to the position of VP Marketing. Mr. Shaxon is a capital markets professional with 20+ year's experience leading corporate development and finance initia- tives in the natural resource, technology and life sciences sectors. Mr. Shaxon was an early pioneer in the legal cannabis market place under the old MMAR as well as 10 years of consulting experience with the top tier of MMJ public companies in Canada and the USA, such as Cannabis Science, Aurora, THC Biomed, Redecan, and Lexaria. Mr. Shaxon was founder of Sticky Icky Inc. as well as AAA Heidelberg, which partnered with Canopy Growth, and was sold to AgraFlora Organics. Mr. Shaxon has raised millions of dollars in the cannabis sector.お知らせ • Jul 31AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.AREV Brands International Ltd. (CNSX:AREV) entered into a binding letter of intent to acquire a 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California on May 1, 2019. The transaction is subjected to necessary governmental, regulatory and court consents, permits, licenses, waivers and approvals to operate the businesses, compliance with pre- closing covenants and continuing accuracy of each Party’s representations and warranties in all material respects, consents and approvals of third parties and the Canadian Securities Exchange and completion of a satisfactory due diligence investigation. The parties will work together in good faith to negotiate and finalize the acquisition agreement on or before June 1, 2019. AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California on May 1, 2020.お知らせ • Jul 21AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in fundingAREV NanoTec Brands Inc. (CNSX:AREV) announced a private placement of up to 1,600,000 units at a price of CAD 0.10 per unit for gross proceeds of up to CAD 160,000 on June 20, 2020. Each unit is comprised of one common share. The company will pay finder's fees in cash shares or warrants. The transaction is subject to board approval.株主還元AREVCA PharmaceuticalsCA 市場7D0%3.4%2.6%1Y-35.7%-9.2%31.6%株主還元を見る業界別リターン: AREV過去 1 年間で-9.2 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。リターン対市場: AREVは、過去 1 年間で31.6 % のリターンを上げたCanadian市場を下回りました。価格変動Is AREV's price volatile compared to industry and market?AREV volatilityAREV Average Weekly Movementn/aPharmaceuticals Industry Average Movement8.7%Market Average Movement9.7%10% most volatile stocks in CA Market16.1%10% least volatile stocks in CA Market3.7%安定した株価: AREV 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のAREVのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aMike Withrowwww.arevlifesciences.comもっと見るAREV Life Sciences Global Corp. 基礎のまとめAREV Life Sciences Global の収益と売上を時価総額と比較するとどうか。AREV 基礎統計学時価総額CA$2.86m収益（TTM）-CA$1.02m売上高(TTM)CA$183.89k15.5xP/Sレシオ-2.8xPER（株価収益率AREV は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AREV 損益計算書（TTM）収益CA$183.89k売上原価CA$15.66k売上総利益CA$168.23kその他の費用CA$1.19m収益-CA$1.02m直近の収益報告Sep 30, 2022次回決算日該当なし一株当たり利益（EPS）-0.032グロス・マージン91.48%純利益率-555.81%有利子負債／自己資本比率-4.4%AREV の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/16 07:38終値2023/07/20 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AREV Life Sciences Global Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 06AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024.
Board Change • Jun 16No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 20No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Mar 08No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 10AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from BoardAREV Life Sciences Global Corp. announced the resignation of Melvin Maxwell from the Board.
Board Change • Jan 06No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 06AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024.
Board Change • Jun 16No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 20No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Mar 08No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 10AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from BoardAREV Life Sciences Global Corp. announced the resignation of Melvin Maxwell from the Board.
Board Change • Jan 06No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 24Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)Third quarter 2022 results: CA$0.008 loss per share. Revenue: CA$23.1k (down 13% from 3Q 2021). Net loss: CA$240.7k (loss widened 9.4% from 3Q 2021).
Recent Insider Transactions • Nov 20Chairman & CEO recently bought CA$59k worth of stockOn the 11th of November, Michael Withrow bought around 578k shares on-market at roughly CA$0.10 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of CA$59k worth in shares.
Board Change • Nov 16No independent directorsThere are 10 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 29AREV Life Sciences Global Corp. Announces Management ChangesAREV Life Sciences Global Corp. announced the appointment of Dr. Andrew Levinson to the company’s Scientific Advisory Board. Dr. Levinson is dedicated to progressive direction in integrative health, Dr. Levinson is a functional medicine doctor and psychiatrist combining mainstream and alternative approaches together with comprehensive treatments. He has developed and commercialized a line of complementary products branded as “Vitality Health and Wellness" which he sells though his clinics and concierge service. Dr. Levinson received both his Bachelor of Science in Psychobiology and his Medical Doctorate from University of Miami. While at University of Miami, in 1993 Dr. Levinson created and chaired an alternative medicine conference which was integrated into the medical school#s curriculum for both students and professors. He also pursued academia as an Assistant Professor in the Department of Psychiatry at Florida International University’s College of Medicine. Dr. Levinson has affiliation with: the International AIDS Society (IAS), the International Association of Providers of AIDS Care (IAPAC), the American Academy of HIV Medicine (AAHIVM), and the Infectious Disease Society of America (IDSA). The company also announced the resignation of Mr. Kevin Phelps as Chief Operating Officer ("COO") of the Company. Mr. Phelps feels that the Company is at a critical step in its development, and onsite leadership is needed at this time. Due to Mr. Phelps being located in New York, and given the challenges of International travel given the pandemic, he was no longer the best fit for this role. Mr. Phelps will continue on as a member of the Board of Directors of the Company.
Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)Second quarter 2022 results: CA$0.026 loss per share. Revenue: CA$10.2k (down 76% from 2Q 2021). Net loss: CA$772.9k (loss widened 11% from 2Q 2021).
お知らせ • Aug 18AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory BoardAREV Life Sciences Global Corp. announced the appointment of Sateesh Apte MD to the Scientific Advisory Board (the SAB) of AREV. AREV Life Sciences announced the appointment of Sateesh Apte MD to its Scientific Advisory Board, as part of the current scale up for launching clinical studies of SUSTAINNTM for treating Serious Acute Malnutrition in Low & Middle Income Countries. "LMIC". Dr Apte"s expertise in neurological pathogenesis will complement AREV's focus on positioning SUSTAINNTM to address the cognitive preservation of children experiencing serious acute malnutrition, which causes brain damage in millions of malnourished children a year. Said Mike Withrow, CEO of AREV Life Sciences Dr. Apte's appointment to the SAB of AREV is a critical step in successfully designing studies to demonstrate the clinical value of SUSTAINN in treating SAM. Dr. Apte specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences. Dr. Apte"s graduate training was at Haffkine Institute in Mumbai, India, The Pasteur Institute in Paris, France, at Harvard Medical School in Boston and at Stanford University in California. His professional appointments have included active staff positions at the VA Medical Center and Valley Memorial Hospital in Livermore, CA; ValleyCare Medical Center in Pleasanton, CA, and directorships with PainCare Medical Clinic, and the Sleep Disorders Center in San Ramon and Pleasanton, CA. He most recently served as President and CEO of Northern California Physicians Associates Inc. and Alpha Medical Group Inc. (1986-1992) He served as President and CEO of ImmunoScience Inc. in Pleasanton, CA until 2019. Dr. Apte has authored and co-authored a number of articles for medical journals and has several publications pending.
Reported Earnings • May 03Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)Full year 2021 results: CA$0.051 loss per share (up from CA$0.068 loss in FY 2020). Revenue: CA$255.0k (up 34% from FY 2020). Net loss: CA$990.3k (loss narrowed 5.6% from FY 2020). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsThere are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Chairman & CEO Mike Withrow is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 20AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of DirectorsAREV Life Sciences Global Corporation announced the appointment of Brian V. Elliott, B Comm to its Board of Directors. Brian V. Elliott is an international strategist and leader exhibiting over 35 years in Senior Management positions in the pharmaceutical industry and the health related public sectors. He has provided10 years of service with the Irish Government Industrial Development Authority in Ireland, France, and Lesotho.
お知らせ • Apr 09AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating OfficerAREV Life Sciences Global Corp. announced the appointment of Kevin Phelps, CPA as Chief Operating Officer. In its current phase of growth and development, AREV Life Sciences Global Corporation appoints Kevin Phelps, CPA and AREV Board Member to the role of Chief Operating Officer. Kevin Phelps brings 40 years of experience in biotech and general business sectors to AREV. He has served in roles as CEO, CFO and VP Business Development throughout several executive teams.
お知らせ • Feb 18AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory CommitteeAREV Life Sciences Global Corp. announced the appointment of Douglas Sorocco to its Scientific Advisory Committee and IP Council and the company's extension of services with Strategic Health Resources LLC.
お知らせ • Dec 12AREV Life Sciences Settles Pending Litigation with HarveyAREV Life Sciences Global Corp. announced that it has reached a confidential settlement with Matthew Harvey, the vendor of the BC Bud Depot Assets, during a formal mediation prior to Trial. The Company announced on January 31, 2020 that the Company had commenced litigation in the Supreme Court of British Columbia over the breaches of Agreement by the Defendant, Matthew Harvey, the vendor of the BC Bud Depot Assets. The Company is very pleased with the outcome of the mediation, but cannot disclose the details of the settlement as the Mediation process is confidential.
Reported Earnings • Dec 02Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.009 loss per share (vs CA$0.009 loss in 3Q 2020). Revenue: CA$26.5k (down 46% from 3Q 2020). Net loss: CA$219.9k (loss widened 39% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
お知らせ • Dec 01AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million on November 30, 2021. AREV Life Sciences Global Corp. (CNSX:AREV) completed the acquisition of Wright and Well Essentials Inc. on November 30, 2021.
Recent Insider Transactions Derivative • Nov 21Chairman & CEO exercised options to buy CA$200k worth of stock.On the 19th of November, Michael Withrow exercised options to buy 1m shares at a strike price of around CA$0.08, costing a total of CA$80k. This transaction amounted to 11% of their direct individual holding at the time of the trade. Since December 2020, Michael's direct individual holding has increased from 8.29m shares to 9.47m. Company insiders have collectively sold CA$83k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Nov 21Chairman & CEO recently sold CA$125k worth of stockOn the 17th of November, Michael Withrow sold around 499k shares on-market at roughly CA$0.25 per share. This was the largest sale by an insider in the last 3 months. Michael has been a seller over the last 12 months, reducing personal holdings by CA$382k.
Reported Earnings • Aug 28Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: CA$43.2k (down 20% from 2Q 2020). Net loss: CA$695.3k (loss widened 153% from 2Q 2020).
Reported Earnings • Jun 06First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$42.6k (up 25% from 1Q 2020). Net loss: CA$566.5k (loss widened 400% from 1Q 2020).
お知らせ • Jun 02AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based DrugsAREV NANOTEC BRANDS INC. announced that it has expanded its extraction results to Clinical Characterization of Compounds and provides this update of corporate developments consistent with its news announcements. In the first five months of 2021, AREV has advanced its core competencies in extraction systems, functional ingredient production, and natural product formulations, expanding its know-how into innovative plant compound identification and medicinal characterization for utility in the company’s development of advanced-stage nutritional foods and discovery of plant-based drugs (or phytomedicinalization). AREV is engaging scientists to characterize compounds for its proprietary ingredients while building AREV’s team of preclinical drug discovery partners in the company’s rational drug design, driven by molecular epidemiology.
お知らせ • Apr 01AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in fundingOn March 31, 2021, AREV NanoTec Brands Inc. (CNSX:AREV) closed the transaction. The company announced that it has issued 2,680,000 units for gross proceeds of CAD 670,000. The transaction involved participation from strategic investors, including an insider for 400,000 units. the transaction was undersubscribed.
お知らせ • Mar 03Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate DevelopmentAREV NanoTec Brands Inc. announced that the Company has appointed Chad S. Johnson, Esq., as Special Counsel for Corporate Development. Complementing AREVs announced corporate and development activities, Mr. Johnson and his staff will serve AREV in a variety of capacities, including media strategy development, government affairs and legislative advocacy, facilitation of scientific advisory appointments, coordination of trade organization memberships, organization of global scientific conference operations, and management of relationships with clinical societies and academies. Mr. Johnson will also assist in developing collaborations with academic research institutions and private sector partners to accelerate AREVs pre-clinical drug discovery platform.
お知らせ • Feb 25AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of DirectorsAREV NanoTec Brands Inc. announced the addition of Kevin J. Phelps to its Board of Directors. Mr. Phelps has a long history in the biotechnology and drug discovery industries, currently serving as the CEO of Immune Therapeutics Inc., and as Chairman of OyaGen Inc. Mr. Phelps began his career as a CPA with Price Waterhouse Coopers and the executive management team of Eastman Kodak Company and its affiliate, Genencor International Inc., which Mr. Phelps served as CFO and EVP of Business Development. He has also served as CFO of Vaccinex Inc. Mr. Phelps went on to join Trillium Group, LLC.
お知らせ • Feb 20AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory BoardAREV NanoTec Brands Inc. announced the appointment of Dr. Jay Noller to its Scientific Advisory Board. Dr. Jay Noller, PhD, is a globally recognized polymath in agriculture, environmental and earth sciences, archaeology, and visual arts. He has led organizations that provided diverse activities in education, research, extension, and public service relevant to seed production, soils and ecosystem services, small farms and community food systems, integrated pest management, and various approaches to natural resource management. He has served in numerous roles as leader or administrator of several enterprises that provide wheat, potatoes and other food commodities to the world at large as well as to food systems at community level.
お知らせ • Feb 18AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral PathogensAREV NANOTEC BRANDS INC. announced that AREV is utilizing its proprietary extraction technologies and facilitating initial efforts to identify broad spectrum antiviral agents derived from medicinal photochemistry sources including bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia, identified in peer-reviewed publications as presenting a wide range of antiviral activity, and may demonstrate high affinity with viral protease inhibition. AREV’s current efforts to secure the antiviral characteristics of COVID-19’s Mpro which remains as the important drug target against COVID-19 infection, will involve grant solicitation from funding sources for pre-clinical discover include NSF’s Rapid Response Research (RAPID) program to mobilize funding for high priority projects and the NIH Consortium for Advancing Research on Botanical and Other Natural Products (CARBON) Program, working with the National Center for Complementary and Integrative Health (NCCIH) as well as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership and Biomedical Advanced Research and Development Authority (BARDA) to address the COVID-19 pandemic that are directing requests for proposals to numerous biopharmaceutical companies. More than 2,100 plant species globally have the potential for being used as medical plants and it has been estimated, that plant derived drugs constitute as much as 25% of the total therapeutics while in fast developing countries such as India and China, the contribution is as much as 80%.
Is New 90 Day High Low • Feb 11New 90-day high: CA$0.42The company is up 367% from its price of CA$0.09 on 11 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 109% over the same period.
お知らせ • Feb 10AREV Appoints Dr. Roscoe Moore to Join the Advisory BoardAREV NANOTEC BRANDS INC. announced the appointment of Dr. Roscoe Moore DVM, MPH, PhD, Former Assistant United States Surgeon General to the Scientific Advisory Board for AREV Nanotec Brands Inc, to provide strategic planning for AREV drug discovery planning, as a Senior Scientific Advisor.
お知らせ • Feb 05AREV NanoTec Brands Inc. Corporate Update on Latest InnovationArev Nanotec Brands Inc. Corporate update on its continued work with natural materials, specifically Moringa. The company has been working with several plant, fungi and marine biomass including functional mushrooms, hops, frank-incense, myrrh, Kampot pepper, sea cucumber, ginseng and Moringa. Much of this work has been focused on the best way to extract actives and researching target compounds present in each of the natural phyto-matierials. As a result, the company has chosen Moringa to be the candidate for molecular screening for its antiviral properties. The company has secured organic supply from Priceless Farms in Uganda, which is working with AREV's Cambodian subsid-iary to establish Moringa as a permaculture crop on its 12 hectare parcel of land near Phnom Penh. The company will continue to update shareholders as progress is made on what is anticipated to be a fast moving initiative.
お知らせ • Feb 03AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory BoardAREV NanoTec Brands Inc. appointed Dr. Uma V. A. Dhanabalan as Advisory Board. She is a Fellow of the American Academy of Family Physicians, a Diplomat Certified in Cannabinoid Medicine and a Medical Review Officer.
お知らせ • Jan 26AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in fundingAREV NanoTec Brands Inc. (CNSX:AREV) announced a non-brokered private placement of up to of up to 2,900,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 725,000 on January 25, 2021. Each Unit will consist of one common Share and one common share purchase warrant, each whole warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.28 per share, on the date that is 24 months from the date of issuance of the warrants; except that, if over a period of 10 consecutive trading days between the date that is 4 months and a day from the date of issuance of the warrants and the date that the warrants would otherwise expire, the closing price of the company’s common shares on the Canadian Securities Exchange is at or exceeds CAD 0.75, then the company may, at its option, provide written notice to the warrant holders to exercise their warrants within 30 days of the date of the notice, failing which the warrants will expire. Securities issued by the company pursuant to the transaction will be subject to a four month and one day hold period in Canada commencing on the closing date. The company may pay finders’ fees in cash, shares or warrants, or a combination of the forgoing, subject to the Board approval and in accordance with the policies of the Canadian Securities Exchange.
お知らせ • Jan 08AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLCAREV Brands International Ltd. (CNSX:AREV) announced a non brokered private placement of up to 1,000,000 units at a price of CAD 0.10 per unit for gross proceeds of up to CAD 100,000 on January 6, 2020. Each unit consists of one share and one common share purchase warrant. Each warrant is exercisable at a price of CAD 0.15 per share for 12 months from the date of issuance. The transaction included participation from returning strategic investor, Chiron Partners LLC.
分析記事 • Jan 02How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Is New 90 Day High Low • Dec 31New 90-day high: CA$0.22The company is up 175% from its price of CA$0.08 on 24 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 57% over the same period.
Recent Insider Transactions • Dec 31Chairman & CEO recently sold CA$261k worth of stockOn the 24th of December, Michael Withrow sold around 2m shares on-market at roughly CA$0.15 per share. This was the largest sale by an insider in the last 3 months. Michael has been a seller over the last 12 months, reducing personal holdings by CA$87k.
お知らせ • Dec 26AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune BoostAREV NANOTEC BRANDS INC. announced that it has received its' first trial run of its NaturVac Immune Boost. NaturVac is the company's proprietary blended Sea Cucumber, Turmeric and Astaxanthin known to Decrease oxidative stress on the heart and blood vessels, Vitamin D3 known to help to maintain immune function, Zinc known to help to maintain immune function and B12 known to help to form red blood cells. Sea cucumbers are rich in protein, Chondroitin sulphate niacin, and riboflavin and contain substances thought to influence human health, including: Coelomic fluid a compound that functions similarly to white blood cells in humans, Palmitic, stearic, and linoleic acid a fatty acids with potent antioxidant effects, Squalene a compound that acts the precursor to steroids and Triterpenoids a class of compounds thought to slow cancer growth. Naturvac has been formulated to provide pre-emptive approach to maintaining a healthy immune system. The trial run will be marketed under the company's BARE – People Brand.
お知らせ • Dec 17AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP MarketingAREV Brands International Ltd. announced the appointment of Mr. Don Shaxon to the position of VP Marketing. Mr. Shaxon is a capital markets professional with 20+ year's experience leading corporate development and finance initia- tives in the natural resource, technology and life sciences sectors. Mr. Shaxon was an early pioneer in the legal cannabis market place under the old MMAR as well as 10 years of consulting experience with the top tier of MMJ public companies in Canada and the USA, such as Cannabis Science, Aurora, THC Biomed, Redecan, and Lexaria. Mr. Shaxon was founder of Sticky Icky Inc. as well as AAA Heidelberg, which partnered with Canopy Growth, and was sold to AgraFlora Organics. Mr. Shaxon has raised millions of dollars in the cannabis sector.
お知らせ • Jul 31AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.AREV Brands International Ltd. (CNSX:AREV) entered into a binding letter of intent to acquire a 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California on May 1, 2019. The transaction is subjected to necessary governmental, regulatory and court consents, permits, licenses, waivers and approvals to operate the businesses, compliance with pre- closing covenants and continuing accuracy of each Party’s representations and warranties in all material respects, consents and approvals of third parties and the Canadian Securities Exchange and completion of a satisfactory due diligence investigation. The parties will work together in good faith to negotiate and finalize the acquisition agreement on or before June 1, 2019. AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California on May 1, 2020.
お知らせ • Jul 21AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in fundingAREV NanoTec Brands Inc. (CNSX:AREV) announced a private placement of up to 1,600,000 units at a price of CAD 0.10 per unit for gross proceeds of up to CAD 160,000 on June 20, 2020. Each unit is comprised of one common share. The company will pay finder's fees in cash shares or warrants. The transaction is subject to board approval.
